Obesity is increasingly recognized as a complex, chronic disease that plays a significant role in the development, progression, and management of psoriatic disease. Beyond its effects on body weight, obesity contributes to systemic inflammation, alters immune function, influences treatment response, and increases the burden of cardiometabolic comorbidities commonly seen in patients with psoriasis and psoriatic arthritis.

The GRAPPA Advanced Clinical Forum on Obesity brings together internationally recognized experts in endocrinology, obesity medicine, immunology, and patient advocacy to explore the evolving science at the intersection of obesity and psoriatic disease. Through a series of recorded presentations, faculty examine the biological mechanisms linking obesity and inflammation, the impact of weight bias on patient care, advances in adipose tissue immunology, and emerging evidence supporting incretin-based therapies and other weight management strategies.

The program is organized as a progressive educational series, beginning with foundational concepts in obesity as a chronic disease, followed by the immunometabolic relationship between obesity and psoriatic disease, emerging therapeutic approaches, and practical strategies for integrating obesity management into clinical practice.

Whether you are new to obesity medicine or seeking to expand your understanding of its role in psoriatic disease, these presentations provide current evidence, expert perspectives, and practical insights to support comprehensive, patient-centered care.